Owning 44% Shares,institutional Owners Seem Interested in Adicet Bio, Inc. (NASDAQ:ACET),
Adicet Stock Jumps 10% on FDA Fast Track Status for ADI-270
Buy Rating Affirmed for Adicet Bio on Strong Therapy Pipeline and Positive Financial Projections
Express News | Adicet Bio Shares Are Trading Higher After the Company Announced That the FDA Granted It Fast Track Designation to ADI-270 for the Potential Treatment of Patients With Metastatic/advanced Clear Cell Renal Cell Carcinoma
Express News | The FDA Has Granted Fast Track Designation To Adicet Bio's ADI-270 For Metastatic/Advanced Clear Cell Renal Cell Carcinoma Patients Who Have Been Treated With An Immune Checkpoint Inhibitor And A Vascular Endothelial Growth Factor Inhibitor
Express News | Adicet Bio Receives FDA Fast Track Designation for Adi-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
FDA Clears IND Application for Adicet Bio's CAR T Cell Therapy Candidate
Express News | Adicet Bio Announces FDA Clearance Of Its IND Application For ADI-270 In Renal Cell Carcinoma
Express News | Adicet Bio Inc - Phase 1 Clinical Study to Evaluate Safety and Anti-Tumor Activity of Adi-270 in Relapsed/Refractory Rcc Patients
Express News | Adicet Bio Inc - Phase 1 Clinical Study to Be Initiated in 2H 2024; Preliminary Clinical Data Expected in 1H 2025
Express News | Adicet Bio Announces FDA Clearance of Ind Application for Adi-270 in Renal Cell Carcinoma
We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Adicet Bio(ACET.US) Director Sells US$8,437 in Common Stock
Sector Update: Health Care Stocks Rise Wednesday Afternoon
H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $10
Express News | Adicet Bio Shares Are Trading Higher After the Company Was Granted FDA Fast Track Designation to ADI-001 in Lupus Nephritis
Express News | Adicet Bio Says FDA Has Granted Fast Track Designation To ADI-001 For Potential Treatment Of Relapsed/Refractory Class III Or Class IV Lupus Nephritis
Express News | Adicet Bio Receives FDA Fast Track Designation for Adi-001 in Lupus Nephritis
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference